Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2017-10-02 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is titled with a major announcement ('Onxeo Introduces platON™ , a Proprietary Chemistry Platform...') and is explicitly labeled as a 'PRESS RELEASE'. It details strategic updates, pipeline progress (AsiDNA™, belinostat), financial visibility, and lists upcoming events. This structure—a formal announcement of significant business developments, often released to the public and media before or alongside formal regulatory filings—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on introducing a new platform and updating on pipeline progress rather than just summarizing quarterly numbers (which would be ER) or providing a full annual review (10-K), it functions as a major corporate update. Given the options, the content strongly aligns with an Earnings Release (ER) which often includes strategic updates alongside financial context, or potentially a Regulatory Filing (RNS) if it were purely informational. However, the comprehensive nature of the update, including forward-looking statements and pipeline details, suggests it's more substantial than a simple RNS. Since it's a press release announcing key business and pipeline milestones, ER is the closest fit for a major periodic update, although it's not strictly Q3 results (which are mentioned as upcoming). Given the context of major corporate news dissemination, ER is the most appropriate classification for a detailed press release announcing strategic direction and pipeline status.
2017-10-02 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is explicitly titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces the presentation of a new platform ('platON™') and updates on existing drug candidates (AsiDNA™, belinostat, Livatag®). It includes key financial highlights (cash runway until early 2020) and future event schedules, characteristic of an initial announcement of significant corporate and scientific developments. This structure strongly suggests an Earnings Release (ER) or a general press release announcing business updates. Since it focuses on scientific/pipeline updates and financial outlook rather than just quarterly figures, and it is a formal announcement, it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less structured. Given the content structure (headline announcement, key bullet points, management quotes, future events), ER is the most appropriate fit for a major operational update press release. FY 2017
2017-10-02 French
Communications during bidding periods / Other releases
Regulatory Filings Classification · 1% confidence The document is titled 'PRESS RELEASE' and announces 'compelling preclinical data' regarding the combination of two proprietary compounds (AsiDNA™ and belinostat). It details scientific findings, future development plans, and includes a section on 'Upcoming events' and 'About Onxeo'. This format is characteristic of an initial announcement of significant operational or scientific progress, rather than a formal regulatory filing like a 10-K, an official Audit Report (AR), or a comprehensive Interim Report (IR). It is not a transcript (CT) or a formal proxy/remuneration document (DEF 14A/PSI). Since it is a press release announcing scientific/business updates, it fits best under the general 'Regulatory Filings' (RNS) category, which often serves as a catch-all for important, non-standardized corporate announcements, or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is focused purely on R&D data. Given the nature of the announcement (preclinical data and patent filing), RNS is the most appropriate general regulatory announcement category.
2017-09-28 English
Communiqués en période d’offre / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo, a biotechnology company, dated September 28, 2017, announcing 'convincing preclinical data' regarding the combination of its drug candidates AsiDNA™ and belinostat. It details scientific findings, mentions future plans (including an ambitious publication schedule starting at the AACR congress in April 2018), and provides contact information for Investor Relations and Press. This content is characteristic of an announcement intended to inform the market about scientific progress, which often precedes a formal regulatory filing or is released as a general corporate update. Since it is not a full Annual Report (10-K), a formal Earnings Release (ER), or a transcript (CT), and it is a specific corporate announcement about R&D progress and pipeline strategy, it fits best under the general category for corporate news that doesn't fit the highly specific financial or governance codes. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, material corporate announcements that are not explicitly defined elsewhere, although 'Investor Presentation' (IP) or 'Management Reports' (MDA) could be considered if the content were more focused on strategy/outlook rather than raw data announcement. However, as a press release announcing scientific data and future plans, RNS is the most appropriate fallback for a material, non-periodic announcement.
2017-09-28 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document text is an announcement titled "Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®". It explicitly details the time, dial-in information, and speakers for an upcoming conference call intended to discuss study data. This structure—announcing a call to discuss results or data—is characteristic of a Call Transcript (CT) if the transcript itself were provided, or an Earnings Release (ER) if it were about financial results. Since the document is an announcement *about* a call where data will be discussed, and it provides all the logistical details for that call, it most closely aligns with the definition of a Call Transcript (CT), as it is the precursor or context for a discussion that will be transcribed. However, looking at the definitions, 'CT' is defined as the 'Full text transcript of company conference calls'. This document is the *invitation* or *notice* for the call, not the transcript itself. It is announcing a call to comment on study findings, which is often associated with an Earnings Release (ER) if it were financial, or a general announcement. Given the content is focused entirely on setting up the call and providing context for the data to be discussed, and it is not a formal financial report (10-K, IR, ER), it fits best as a precursor to a discussion. Since it is not a formal report, and the focus is the call itself, 'CT' is the most relevant category, even if it's the announcement *for* the call rather than the transcript itself, as it pertains directly to the event that generates a transcript. If the document were purely an announcement of results without the call details, ER would be better. If it were a short notice about a report, RPA/RNS would apply. Because the central theme is the conference call logistics and purpose, CT is the strongest fit among the options provided for this type of event announcement.
2017-09-18 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Call Transcript Classification · 1% confidence The document text is a press release announcing a conference call scheduled for September 18, 2017, to discuss the main results of the Phase III Livatag (ReLive) study. It provides details about the call (time, dial-in numbers, speakers) and background information on the disease (HCC) and the study itself. The key indicator is the structure: it announces an event (a conference call) to discuss results, rather than being the full transcript of that call or the comprehensive financial report itself. Since it is an announcement related to company performance discussion, and it explicitly mentions a 'Conférence Téléphonique' (Conference Call), the most appropriate classification is Call Transcript (CT), assuming the content provided is the announcement leading up to the call, or if the content *is* the transcript, it fits CT. However, given the context of financial filings, this announcement is primarily about scheduling the discussion of results. If the document *were* the full transcript, it would be CT. If it is the announcement *before* the call, it often falls under ER (Earnings Release) if results are included, or RNS (Regulatory Filings) if it's just an announcement of a call. Since the text details the context of the results presentation and the call itself, it strongly aligns with the purpose of an Earnings Release (ER) or a Call Transcript (CT). Given the detailed scientific/clinical context and the explicit mention of a conference call to 'commenter les principaux résultats' (comment on the main results), it functions as the primary communication vehicle for period results, making ER or CT likely. Since the text is not the Q&A transcript but the announcement *for* the call, ER (Earnings Release) is often used for the initial release of period results, even if a call follows. However, the structure is highly indicative of a Call Transcript announcement or the transcript itself if the Q&A followed. Since the document is structured around the call details and the presentation of study results, and it is not a formal 10-K or IR, 'Call Transcript' (CT) is the best fit if we interpret this as the material surrounding the call where results are discussed, or ER if we focus on the results announcement aspect. Given the explicit focus on the conference call details and the presentation of clinical data, CT is slightly more precise than ER, which usually focuses purely on financial metrics. I will classify it as CT based on the central theme being the conference call itself.
2017-09-18 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.